- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2012 (2012), Article ID 950658, 17 pages
Salinomycin as a Drug for Targeting Human Cancer Stem Cells
1Institute of Immunology, University of Heidelberg, Im Neuenheimer Feld 305, 69120 Heidelberg, Germany
2Center and Network for Targeted Oncology, Clinical Research Division, Muehlackerweg 8, 69239 Heidelberg, Germany
Received 23 August 2012; Accepted 4 October 2012
Academic Editor: Adam Huczynski
Copyright © 2012 Cord Naujokat and Roman Steinhart. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Citations to this Article [21 citations]
The following is the list of published articles that have cited the current article.
- Jacek Rutkowski, Izabela Borowicz, Joanna Wietrzyk, Ewa Maj, and Bogumil Brzezinski, “One-pot synthesis and cytotoxicity studies of new Mannich base derivatives of polyether antibiotic-Lasalocid acid,” Bioorganic & Medicinal Chemistry Letters, vol. 23, no. 18, pp. 5053–5056, 2013.
- Won Duk Joo, Irene Visintin, and Gil Mor, “Targeted cancer therapy – Are the days of systemic chemotherapy numbered?,” Maturitas, 2013.
- José N. Onuchic, Patricia A. Jennings, and Eshel Ben-Jacob, “Learning from cancer how to defeat bacteria,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 9, pp. 3212–3213, 2013.
- Justin M. David, Tori A. Owens, and Sonali P. Barwe, “Gramicidin A Induces Metabolic Dysfunction and Energy Depletion Leading to Cell Death in Renal Cell Carcinoma Cells,” Molecular Cancer Therapeutics, vol. 12, no. 11, pp. 2296–2307, 2013.
- Petra Huehnchen, and Matthias Endres, “Assessment of Paclitaxel Induced Sensory Polyneuropathy with "Catwalk" Auto mated Gait Analysis in Mice,” Plos One, vol. 8, no. 10, 2013.
- Björn Borgström, Xiaoli Huang, Martin Pošta, Cecilia Hegardt, Stina Oredsson, and Daniel Strand, “Synthetic modification of salinomycin: selective O-acylation and biological evaluation,” Chemical Communications, vol. 49, no. 85, pp. 9944, 2013.
- Olajumoke Omolara Ojo, and Smrati Bhadauria, “Dose-Dependent Adverse Effects of Salinomycin on Male Reproductive Organs a nd Fertility in Mice,” Plos One, vol. 8, no. 7, 2013.
- Panagiota A. Sotiropoulou, Michael S. Christodoulou, Alessandra Silvani, Christel Herold-Mende, and Daniele Passarella, “Chemical approaches to targeting drug resistance in cancer stem cells,” Drug Discovery Today, 2014.
- Jan Janczak, Jacek Rutkowski, and Bogumil Brzezinski, “Spectroscopic, crystallographic and theoretical studies of lasalocid comple x with ammonia and benzylamine,” Spectrochimica Acta Part A-Molecular and Biomolecular Spectroscopy, vol. 125, pp. 297–307, 2014.
- Xiaoli Huang, Björn Borgström, Linda Månsson, Lo Persson, Stina Oredsson, Cecilia Hegardt, and Daniel Strand, “Semisynthesis of SY-1 for Investigation of Breast Cancer Stem Cell Selectivity of C-Ring-Modified Salinomycin Analogues,” ACS Chemical Biology, pp. 140529132416003, 2014.
- Rosi Bissinger, Abaid Malik, Kashif Jilani, and Florian Lang, “Triggering of Erythrocyte Cell Membrane Scrambling by Salinomycin,” Basic & Clinical Pharmacology & Toxicology, 2014.
- Susan D. Mertins, “Cancer stem cells,” Anti-Cancer Drugs, vol. 25, no. 4, pp. 353–367, 2014.
- Jiří Hatina, “Cancer stem cells as a therapeutic target of the future,” Clinical Investigation, vol. 4, no. 4, pp. 289–291, 2014.
- Justin M. David, Tori A. Owens, Landon J. Inge, and Ross M. Bremner, “Gramicidin A Blocks Tumor Growth and Angiogenesis through Inhibition of Hyp oxia-Inducible Factor in Renal Cell Carcinoma,” Molecular Cancer Therapeutics, vol. 13, no. 4, pp. 788–799, 2014.
- Michal Antoszczak, Ewa Maj, Joanna Stefanska, Joanna Wietrzyk, Jan Janczak, and Bogumil Brzezinski, “Synthesis, antiproliferative and antibacterial activity of new amides of sa linomycin,” Bioorganic & Medicinal Chemistry Letters, vol. 24, no. 7, pp. 1724–1729, 2014.
- Yonghe Li, Pui Kai Li, Michael J. Roberts, Rebecca Arend, Rajeev S. Samant, and Donald J. Buchsbaum, “Multi-targeted therapy of cancer by niclosamide: A new application for an old drug,” Cancer Letters, 2014.
- Fatima Ismail, and David A. Winkler, “Getting to the Source: Selective Drug Targeting of Cancer Stem Cells,” ChemMedChem, 2014.
- Wolfgang Boehmerle, Hanna Muenzfeld, Andreas Springer, Petra Huehnchen, and Matthias Endres, “Specific targeting of neurotoxic side effects and pharmacological profile of the novel cancer stem cell drug salinomycin in mice,” Journal of Molecular Medicine, 2014.
- Florian Kopp, Adam Hermawan, Prajakta Shirish Oak, Annika Herrmann, and Ernst Wagner, “Salinomycin treatment reduces metastatic tumor burden by hampering cancer c ell migration,” Molecular Cancer, vol. 13, 2014.
- Roberto Würth, Federica Barbieri, and Tullio Florio, “New Molecules and Old Drugs as Emerging Approaches to Selectively Target Human Glioblastoma Cancer Stem Cells,” BioMed Research International, vol. 2014, pp. 1–11, 2014.
- Ae-Ran Choi, Ju-Hwa Kim, and Sungpil Yoon, “ Sensitization of Cancer Cells through Reduction of Total Akt and Downregulation of Salinomycin-Induced pAkt, pGSk3 β , pTSC2, and p4EBP1 by Cotreatment with MK-2206 ,” BioMed Research International, vol. 2014, pp. 1–8, 2014.